Exelixis vs Moderna: revenue, profit, margins and growth compared
Exelixis brought in $2.3B of revenue in fiscal 2025, Moderna $1.9B in fiscal 2025. Revenue changed by +7.0% at Exelixis and -39.9% at Moderna on the year before, so Exelixis grew faster. Exelixis kept 33.7% of its revenue as net profit, Moderna -145.2%. Free cash flow was $875.8M at Exelixis and -$2.1B at Moderna.
Fiscal years as each company reports them; the two may end in different months.
Questions about Exelixis and Moderna
Which is bigger by revenue, Exelixis or Moderna?
Exelixis is bigger by revenue: $2.3B in fiscal 2025, against $1.9B for Moderna in fiscal 2025.
Which keeps more of its revenue as profit, Exelixis or Moderna?
Exelixis had a net margin of 33.7% in fiscal 2025; Moderna had -145.2% in fiscal 2025.
Which grew revenue faster, Exelixis or Moderna?
In their latest fiscal years revenue changed by +7.0% at Exelixis and -39.9% at Moderna.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.